Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion
In a significant move for its growth and development, Diamyd Medical Aktiebolag has announced it will enter into equity financing agreements with U.S. sector-specialist investors to secure up to $125 million in funding. This financing is poised to enhance the company’s cash position and facilitate its ongoing clinical efforts. Alongside this strategic financial initiative, the company is also proud to announce the full enrollment of its pivotal Phase 3 trial, DIAGNODE-3, aimed at evaluating retogatein (rhGAD65) for the treatment of type 1 diabetes.
On March 23, 2026, the Board of Directors approved a directed issue of 17,226,500 new Class B shares at a subscription price of SEK 13.54 per share. This translates to approximately SEK 233 million before transaction costs. The financing structure also includes the issuance of 46,649,362 warrants, which would enable investors to subscribe for additional shares, significantly bolstering the company’s capital position. If all warrants are exercised, the gross proceeds are anticipated to reach about SEK 1,166 million.
Ulf Hannelius, CEO of Diamyd Medical, expressed enthusiasm over this financing round: "We are pleased to welcome leading U.S. sector specialist investors at this pivotal stage. Their participation brings deep sector expertise and strong alignment with the U.S. market, which will be central to our future development and commercialization strategy."
The completion of the DIAGNODE-3 trial, which involves 321 patients across 57 clinical sites in Europe and the U.S., marks a crucial milestone for the company. The trial focuses on retogatein, an investigational antigen-specific immunotherapy designed for type 1 diabetes patients with the HLA DR3-DQ2 genotype. This specific target group represents a substantial portion of individuals with type 1 diabetes, making results from this trial highly anticipated. Results from an interim analysis of this trial are expected on March 27, 2026, highlighting the efficacy of the treatment.
The funds generated from these financing agreements will be utilized primarily for the completion of the DIAGNODE-3 trial and to prepare for the future commercialization of retogatein. The move to bring in U.S. investors not only ensures financial backing but also aims to enhance the reputation and liquidity of Diamyd Medical's shares by collaborating with reputable institutional investors who possess in-depth sector knowledge.
In reference to the involved investors, names like Perceptive Advisors, Vestal Point Capital, RA Capital Management, and several others were highlighted as key participants in this funding round, showcasing significant confidence in the company’s potential for growth.
As part of this financing, the company anticipates the completion of additional shares to promote extensive growth and shared profit among its stakeholders. The overall strategy outlined by the Board of Directors indicates a preference for directed issuances over a rights issue, a decision aimed at minimizing market risks and facilitating faster capital acquisition. With significant funding secured and the completion of the crucial Phase 3 trial, the future appears promising for Diamyd Medical as it seeks to navigate the complex landscape of type 1 diabetes treatment innovations.
Diamyd Medical continues to develop and innovate within the field of precision medicine for type 1 diabetes, setting its sights on delivering groundbreaking therapies to improve the lives of individuals affected by this condition. With expertise, funding, and strategic collaborations, Diamyd is positioned to lead in this vital area of healthcare. The company is actively fostering transparency and communication with its stakeholders and looks forward to sharing ongoing developments as they emerge.
Contact Information:
For inquiries, please reach out to:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: [email](mailto:
Niklas Axelsson, CFO
Phone: +46 72 528 23 49
E-mail: [email](mailto:
This news marks an exciting chapter in Diamyd Medical’s ongoing journey as a pioneer in biotechnology, poised for impactful contributions to healthcare solutions.
On March 23, 2026, the Board of Directors approved a directed issue of 17,226,500 new Class B shares at a subscription price of SEK 13.54 per share. This translates to approximately SEK 233 million before transaction costs. The financing structure also includes the issuance of 46,649,362 warrants, which would enable investors to subscribe for additional shares, significantly bolstering the company’s capital position. If all warrants are exercised, the gross proceeds are anticipated to reach about SEK 1,166 million.
Ulf Hannelius, CEO of Diamyd Medical, expressed enthusiasm over this financing round: "We are pleased to welcome leading U.S. sector specialist investors at this pivotal stage. Their participation brings deep sector expertise and strong alignment with the U.S. market, which will be central to our future development and commercialization strategy."
The completion of the DIAGNODE-3 trial, which involves 321 patients across 57 clinical sites in Europe and the U.S., marks a crucial milestone for the company. The trial focuses on retogatein, an investigational antigen-specific immunotherapy designed for type 1 diabetes patients with the HLA DR3-DQ2 genotype. This specific target group represents a substantial portion of individuals with type 1 diabetes, making results from this trial highly anticipated. Results from an interim analysis of this trial are expected on March 27, 2026, highlighting the efficacy of the treatment.
The funds generated from these financing agreements will be utilized primarily for the completion of the DIAGNODE-3 trial and to prepare for the future commercialization of retogatein. The move to bring in U.S. investors not only ensures financial backing but also aims to enhance the reputation and liquidity of Diamyd Medical's shares by collaborating with reputable institutional investors who possess in-depth sector knowledge.
In reference to the involved investors, names like Perceptive Advisors, Vestal Point Capital, RA Capital Management, and several others were highlighted as key participants in this funding round, showcasing significant confidence in the company’s potential for growth.
As part of this financing, the company anticipates the completion of additional shares to promote extensive growth and shared profit among its stakeholders. The overall strategy outlined by the Board of Directors indicates a preference for directed issuances over a rights issue, a decision aimed at minimizing market risks and facilitating faster capital acquisition. With significant funding secured and the completion of the crucial Phase 3 trial, the future appears promising for Diamyd Medical as it seeks to navigate the complex landscape of type 1 diabetes treatment innovations.
Diamyd Medical continues to develop and innovate within the field of precision medicine for type 1 diabetes, setting its sights on delivering groundbreaking therapies to improve the lives of individuals affected by this condition. With expertise, funding, and strategic collaborations, Diamyd is positioned to lead in this vital area of healthcare. The company is actively fostering transparency and communication with its stakeholders and looks forward to sharing ongoing developments as they emerge.
Contact Information:
For inquiries, please reach out to:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: [email](mailto:
Niklas Axelsson, CFO
Phone: +46 72 528 23 49
E-mail: [email](mailto:
This news marks an exciting chapter in Diamyd Medical’s ongoing journey as a pioneer in biotechnology, poised for impactful contributions to healthcare solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.